| Contributors: |
De Leo, Simone; D'Elia, Silvia; Grani, Giorgio; Dondi, Francesco; Bertagna, Francesco; Puxeddu, Efisio; Morelli, Silvia; Piovesan, Alessandro; Nervo, Alice; Zatelli, MARIA CHIARA; Gagliardi, Irene; Teresa Sam(`(a)), Maria; Aimaretti, Gianluca; Crocetti, Umberto; Massa, Michela; Deandrea, Maurilio; Retta, Francesca; Pagano, Loredana; Rossi, Mattia; Solaroli, Erica; Pezzullo, Luciano; Grazia Chiofalo, Maria; Pontecorvi, Alfredo; Pio Lombardi, Celestino; Antonelli, Alessandro; Patrizio, Armando; Messuti, Ilaria; Magri, Flavia; Spiazzi, Giovanna; Ceresini, Graziano; Bruno, Rocco; Sparano, Clotilde; Centanni, Marco; Crescenzi, Anna; Tallini, Giovanni; Marotta, Vincenzo; Madeo, Bruno; Mian, Caterina; Filetti, Sebastiano; Durante, Cosimo; Fugazzola, Laura |
| Description: |
Background There is some controversy on the potential relationship between autoimmune processes and clinicopathological features as well as prognosis of differentiated thyroid cancer (DTC), and the evidence is limited by its largely retrospective nature. We examined the relationship between the presence of autoimmune thyroiditis and 1-year thyroid cancer treatment outcomes in a large, multi-center study, using prospectively collected data. Methods We included data from consecutive DTC patients enrolled in the Italian Thyroid Cancer observatory (ITCO) database (NCT04031339). We divided the groups according to the presence (AT) or absence (noAT) of associated autoimmune thyroiditis. We used propensity score matching to compare the clinical features and outcomes between the 2 groups at 1-year follow-up. Results We included data from 4233 DTC patients, including 3172 (75%) females. The American Thyroid Association (ATA) risk levels were as follows: 51% (2160/4233) low risk, 41.3% (1750/4233) intermediate risk, and 7.6% (323/4233) high risk. There were 1552 patients (36.7%) who had autoimmune thyroiditis. Before propensity score matching, AT patients were significantly younger, and had a smaller and bilateral tumor (p |